Psyence Biomedical Announces First Patient Dosed In Phase Iib Clinical Trial Evaluating NPX-5 For Treatment Of Adjustment Disorder In Patients With Cancer In Palliative Care Setting

Benzinga Newsdesk www.benzinga.com Positive 81.2%

Neg 0% Neu 0% Pos 81.2%

Comments

No comments yet. Be the first!